Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors

16 juli 2021 bijgewerkt door: Jiangsu HengRui Medicine Co., Ltd.

A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of New Formulation SHR-1316 in Subjects With Advanced Tumors

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of the new formulation SHR-1316 in subjects with advanced tumors.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Verwacht)

15

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Age ≥18 years.
  2. Histologically or cytologically confirmed advanced cancer in patients who are fail to current standard therapy or lack of effective therapy.
  3. Estimated life expectancy ≥12 weeks.
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  5. Adequate organ functions.
  6. If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment dose.
  7. Patients must be willing and able to provide written informed consent prior to the performance of any study-specific procedure.

Exclusion Criteria:

  1. Known history of hypersensitivity to any components of the SHR-1316 product.
  2. Patient- Prior treatment with the following agents:

    1. "Check-point inhibitors", including Programmed death receptor-1 (PD-1), PD-L1;
    2. Receipt of investigational agents within 4 weeks prior to study treatment;
    3. Current treatment on another therapeutic clinical trial, unless the observational (non-interventional) clinical trials or follow-up of interventional clinical trials;
    4. Any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy, target therapy, biotherapy or tumor embolization), administered within 4 weeks prior to study treatment; or within 6 weeks in the case of certain therapies (e.g., mitomycin C and nitrosoureas). Any such, unless discussed and explained with the sponsor;
    5. Anticipated need for any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy, or biotherapy) during SHR-1316 treatment; except palliative radiotherapy;
    6. Receipt of any anti-cancer vaccines; receipt of immunomodulatory drugs within 4 weeks prior to study treatment; topical, nasal spray and inhaled corticosteroids as well as systemic steroid therapy in physiological doses (such as: prednisone ≤10 mg/day) are acceptable.
  3. Patients have unrecovered (ie, to NCI CTCAE grade ≤1) from all toxicity associated with previous treatments (exception: patients may enter with continuing alopecia irrespective of CTCAE grade; grade 2 peripheral nerve diseases).
  4. Known Active central nervous system (CNS) metastases; Patients who had previously received brain or meningeal metastasis therapy, who were clinically stable for at least 8 weeks, and who had stopped systemic sex hormone therapy (such as: prednisone > 10 mg/day) for more than 4 weeks were included.
  5. Subjects with active autoimmune disease, history of autoimmune diseases, including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.
  6. Active or history of immune deficiency, such as human immunodeficiency virus (HIV) infection; History of organ transplantation.
  7. History or evidence of cardiovascular (CV) risk including any of the following: Congestive heart failure (Class >2) as defined by the New York Heart Association functional classification system (NYHA), unstable angina pectoris, Recent (within the past 12 months) history of myocardial infarction, clinically significant supraventricular or ventricular arrhythmias need treatment or intervention.
  8. Patients with clinically significant ECG abnormalities (QT interval corrected for rate by Fridericia's formula [QTcF] >470 msec for female and >450 msec for male on the ECG obtained at Screening).
  9. Active infection that need drug intervention or an unexplained fever >38.5°C (fever caused by cancer can be included according to the judgement of the researcher).
  10. Active pulmonary tuberculosis infection.
  11. Positive for Hepatitis B or C.
  12. Known history of psychoactive drug abuse, alcohol abuse or drug use.
  13. Known history of any other malignant cancer within past 3 years. Exceptions: completely resected basal cell carcinoma and squamous cell carcinoma of the skin; and completely resected carcinoma in situ of cervix.
  14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Fundamentele wetenschap
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Behandelingsgroep
SHR-1316 administrated intravenously (IV) at protocol defined dose levels

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
The incidence and severity of adverse events/serious adverse events (based on NCI-CTC AE 5.0)
Tijdsspanne: approximately 1 year
approximately 1 year
Maximum plasma concentration (Cmax)
Tijdsspanne: approximately 1 year
approximately 1 year
Time to maximum concentration (Tmax)
Tijdsspanne: approximately 1 year
approximately 1 year
Area under the concentration-time curve from time zero to time(AUC0-t)
Tijdsspanne: approximately 1 year
approximately 1 year
Area under the concentration-time curve extrapolated to infinity (AUC0-∞.)
Tijdsspanne: approximately 1 year
approximately 1 year
Elimination half-life (t1/2)
Tijdsspanne: approximately 1 year
approximately 1 year
Clearance (CL)
Tijdsspanne: approximately 1 year
approximately 1 year
Volume of distribution (Vz)
Tijdsspanne: approximately 1 year
approximately 1 year
Trough concentration (Cmin)
Tijdsspanne: approximately 1 year
approximately 1 year
Accumulatio of ratio (Rac)
Tijdsspanne: approximately 1 year
approximately 1 year

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Immunogenicity of SHR-1316
Tijdsspanne: approximately 1 year
Anti-SHR-1316 antibody (ADA), neutralizing antibody (Nab)
approximately 1 year
Objective response rate (ORR)
Tijdsspanne: approximately 1 year
approximately 1 year
Progression-free survival (PFS)
Tijdsspanne: approximately 1 year
approximately 1 year
Duration of response (DoR)
Tijdsspanne: approximately 1 year
approximately 1 year
Disease control rate (DCR)
Tijdsspanne: approximately 1 year
approximately 1 year
Overall survival (OS)
Tijdsspanne: approximately 1 year
approximately 1 year

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Verwacht)

10 augustus 2021

Primaire voltooiing (Verwacht)

10 februari 2022

Studie voltooiing (Verwacht)

31 juli 2022

Studieregistratiedata

Eerst ingediend

12 juli 2021

Eerst ingediend dat voldeed aan de QC-criteria

16 juli 2021

Eerst geplaatst (Werkelijk)

28 juli 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 juli 2021

Laatste update ingediend die voldeed aan QC-criteria

16 juli 2021

Laatst geverifieerd

1 juli 2021

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • SHR-1316-I-103

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren